The objective of this study was to assess the impact of manufacturing-scale, freeze-thaw conditions on aggregation and subvisible particle formation of a monoclonal antibody solution (mAb-A; IgG1) using a small-scale model.
W. Aaron Pruett
Advertisement
W. Aaron Pruett is drug product process engineer, Novavax.
Articles by W. Aaron Pruett
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
2
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
3
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
4
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
5